The GPATCH2 Knockout HeLa Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal HeLa cell population with targeted disruption of the GPATCH2 gene. This loss-of-function model enables investigation of GPATCH2-dependent RNA processing and splicing regulation in a widely used human cervical epithelial cell line. The polyclonal format preserves heterogeneous knockout genotypes across the population, facilitating robust functional genomics studies without clonal selection bias. No specific editing pattern is implied; rather, the pool reflects diverse Cas9-induced indels at the target locus, collectively abrogating GPATCH2 protein expression. This product is suitable for researchers examining spliceosome dynamics and gene expression control mechanisms.
The host HeLa cell line is an HPV-18 positive cervical adenocarcinoma model derived from a human cervical epithelial tumor. HeLa cells are among the most extensively characterized immortalized cell lines in biomedical research, offering advantages such as ease of culture, rapid proliferation, and extensive experimental toolkit availability. Their epithelial origin and transformed phenotype make them particularly relevant for studying cancer cell biology, including RNA metabolism and splicing alterations. The presence of HPV-18 oncogenes provides a distinct background for investigating how viral factors intersect with host splicing machinery.
GPATCH2 encodes a G-patch domain-containing RNA-binding protein that functions in pre-mRNA splicing as part of the spliceosome. It interacts directly with core spliceosomal components SF3A1 and SF3B1, which are subunits of the U2 snRNP, facilitating proper splice site recognition and intron removal. Disruption of GPATCH2 impairs these interactions, likely leading to aberrant splicing of transcripts involved in cell cycle progression and apoptosis. The mechanistic summary indicates that GPATCH2 knockout perturbs normal RNA processing, potentially altering the expression of downstream targets and disrupting cellular homeostasis through mis-splicing events.
In the HeLa cellular context, loss of GPATCH2 provides a valuable model to dissect splicing-dependent regulatory networks in cervical cancer. Given that GPATCH2 is not well characterized, this knockout model fills a critical gap in understanding how G-patch proteins influence oncogenic processes. HeLa cells offer a hyperproliferative background with deregulated splicing, making them ideal for studying how GPATCH2 ablation impacts cancer-relevant phenotypes such as proliferation and survival. This model thus enables the exploration of GPATCH2 as a potential vulnerability in cancer cells.
Researchers can utilize this polyclonal knockout product in a variety of assays to investigate splicing regulation and cancer cell biology. Representative techniques include RNA-seq splicing analysis to detect global splicing changes, RT-PCR for specific splicing variant validation, western blotting to confirm protein loss and downstream effects, and proliferation and apoptosis assays to assess functional consequences. Immunofluorescence and co-immunoprecipitation can further delineate GPATCH2 localization and interactions with spliceosomal partners. For further details and ordering information, please contact Ascent Research.
